Arévalo C, Herrmann F, Aguirre E, Vera J
Unidad Banco de Sangre, Instituto de Hematología Rodolfo Virchow. Valdivia, Chile.
Rev Med Chil. 1992 Feb;120(2):163-7.
A direct 2 stage enzymatic test and the direct anti gamma globulin test were used to predict hemolytic disease of the newborn. Maternal allo-antibodies were determined in cord blood of all newborns from April to June 1988. 0.25% bromelase was used for the 2 Stage Enzymatic Test and a polyspecific anti-gammaglobulin serum was used for the Anti Gamma Globulin Test. Of 618 newborns 97 had parental ABO heterospecificity. Maternal allo-antibodies were present in 20 cases (3.2%). 20 of 86 fullterm newborns developed jaundice presumably due to ABO incompatibility. Blood exchange was required in 6, while phototherapy was sufficient in the rest. The 2 Stage Enzymatic Test was positive in 20 of these cases and the Anti Gamma Globulin Test was positive in 10. Thus, these tests may be used to predict hemolytic disease of the newborn due to ABO incompatibility.
采用直接两步酶试验和直接抗γ球蛋白试验预测新生儿溶血病。对1988年4月至6月出生的所有新生儿的脐血进行母体同种抗体检测。两步酶试验使用0.25%的菠萝蛋白酶，抗γ球蛋白试验使用多特异性抗γ球蛋白血清。在618例新生儿中，97例父母ABO血型不同。20例（3.2%）存在母体同种抗体。86例足月儿中有20例出现黄疸，推测是由于ABO血型不相容所致。其中6例需要换血，其余采用光疗即可。在这些病例中，两步酶试验20例呈阳性，抗γ球蛋白试验10例呈阳性。因此，这些试验可用于预测ABO血型不相容所致的新生儿溶血病。
